Indication & Dosage |
|
|
Intravenous |
CMV INFECTIONS |
Adult:
Induction: 5 mg/kg every 12 hr for 14-21 days. Maintenance: 5 mg/kg once daily for 7 days per wk or 6 mg/kg once daily for 5 days per wk. Dose to be given by IV infusion. |
|
Intravenous |
PREVENTION OF CMV INFECTIONS IN IMMUNOCOMPROMISED PATIENTS |
Adult:
For patients receiving immunosuppressants after organ transplant: Initially, 5 mg/kg every 12 hr for 7-14 days followed by maintenance therapy: 5 mg/kg/day as a single dose for 7 days per wk or 6 mg/kg/day for 5 days per wk. Dose to be given as IV infusion. |
|
Ophthalmic |
CMV RETINITIS |
Adult:
Induction: 5 mg/kg every 12 hr for 14-21 days. Maintenance: 5 mg/kg once daily for 7 days per wk or 6 mg/kg once daily for 5 days per wk. Dose to be given by IV infusion. |
|
|
|
Administration |
Should be taken with food. |
|
|
Precautions |
Renal impairment; preexisting cytopenias or history of cytopenic reactions to drugs; child; contraceptive precautions to be followed during and at least 90 days thereafter; care in administering only into veins with good blood flow. Avoid contact with the skin and eyes. Maintain adequate hydration during infusion. Monitor WBC and platelet counts regularly during treatment. Eye examinations should be conducted at least once every 4-6 wk during treatment for CMV retinitis |
|
|
Adverse Drug Reactions |
Haematolgical disturbances; marrow depression; GI disturbances; fever, rash and abnormal LFTs; irritation and phlebitis at inj site. Less frequent: CV, CNS, metabolic, musculoskeletal, respiratory, urogenital, ocular effects, cutaneous symptoms and increased serum-creatinine and BUN concentration. Potential risk of testicular effects and female fertility. |
|
|
Interactions |
Renal clearance reduced by probenecid; imipenem cilastatin (generalised seizures); zidovudine; didanosine; additive toxic effects with myelosuppressants; oral mycophenolate mofetil. |
|
|